David A. Siegel Coherus Bio Sciences, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 249,600 shares of CHRS stock, worth $272,064. This represents 0.0% of its overall portfolio holdings.

Number of Shares

249,600

Previous 211,600 17.96%

Holding current value

$272,064

Previous $366,000 29.23%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.99 - $1.8 $37,620 - $68,400	38,000 Added 17.96%	249,600 $259,000
Q2 2024 Aug 14, 2024	BUY	$1.58 - $2.51 $7,110 - $11,294	4,500 Added 2.17%	211,600 $366,000
Q1 2024 May 15, 2024	SELL	$2.02 - $3.14 $54,540 - $84,780	-27,000 Reduced 11.53%	207,100 $494,000
Q4 2023 Feb 14, 2024	BUY	$1.59 - $3.85 $331,356 - $802,340	208,400 Added 810.89%	234,100 $779,000
Q3 2023 Nov 14, 2023	SELL	$3.74 - $5.45 $166,430 - $242,525	-44,500 Reduced 63.39%	25,700 $96,000
Q2 2023 Aug 14, 2023	SELL	$3.79 - $8.3 $91,339 - $200,030	-24,100 Reduced 25.56%	70,200 $299,000
Q1 2023 May 15, 2023	SELL	$5.89 - $10.52 $721,525 - $1.29 Million	-122,500 Reduced 56.5%	94,300 $645,000
Q4 2022 Feb 14, 2023	BUY	$5.69 - $10.07 $228,738 - $404,814	40,200 Added 22.76%	216,800 $1.72 Million
Q3 2022 Nov 14, 2022	BUY	$7.17 - $13.87 $539,184 - $1.04 Million	75,200 Added 74.16%	176,600 $1.7 Million
Q2 2022 Aug 15, 2022	BUY	$5.86 - $13.23 $145,328 - $328,104	24,800 Added 32.38%	101,400 $734,000
Q1 2022 May 16, 2022	BUY	$10.92 - $16.41 $836,472 - $1.26 Million	76,600 New	76,600 $989,000
Q3 2020 Nov 16, 2020	SELL	$17.41 - $19.89 $4.09 Million - $4.68 Million	-235,200 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$14.43 - $19.16 $1.79 Million - $2.37 Million	-123,900 Reduced 34.5%	235,200 $4.2 Million
Q1 2020 May 15, 2020	SELL	$11.67 - $22.53 $392,112 - $757,008	-33,600 Reduced 8.56%	359,100 $5.83 Million
Q4 2019 Feb 14, 2020	BUY	$16.33 - $21.37 $2.18 Million - $2.85 Million	133,400 Added 51.45%	392,700 $7.07 Million
Q3 2019 Nov 14, 2019	BUY	$16.3 - $23.37 $1.11 Million - $1.59 Million	68,100 Added 35.62%	259,300 $5.25 Million
Q2 2019 Aug 14, 2019	BUY	$13.1 - $22.1 $1.98 Million - $3.33 Million	150,900 Added 374.44%	191,200 $4.23 Million
Q1 2019 May 15, 2019	BUY	$8.38 - $15.5 $74,582 - $137,950	8,900 Added 28.34%	40,300 $550,000
Q4 2018 Feb 14, 2019	SELL	$8.65 - $16.28 $101,205 - $190,476	-11,700 Reduced 27.15%	31,400 $284,000
Q3 2018 Nov 14, 2018	BUY	$14.45 - $20.25 $93,925 - $131,625	6,500 Added 17.76%	43,100 $711,000
Q2 2018 Aug 14, 2018	BUY	$10.25 - $17.45 $375,150 - $638,670	36,600 New	36,600 $512,000

Others Institutions Holding CHRS

# of Institutions

135

Shares Held

77.9M

Call Options Held

40.7K

Put Options Held

50.1K

View Full List

About Coherus BioSciences, Inc.

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $84.7M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

More about CHRS

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account